

(57) Abstract: The invention provides a GMP compatible method to chemically synthesize proteins which may be advantageously used in compositions for vaccination that are free of biological contaminants. The method uses conventional synthesis of peptides and linking these to yield synthetic proteins that preferably comprise all T cell epitopes for an antigen. Preferably an adjuvant is covalently attached to a synthetic protein to yield a fully synthetic vaccine. The invention is illustrated mainly by using HPV proteins directed immunity as a model.

WO 2005/060993 A1



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Synthetic protein as tumor-specific vaccineField of the invention

5 The present invention relates generally to the field of medicine, and more specifically to induction and/or enhancement of a T cell response directed towards an antigen, using synthetic peptides and linking these to yield synthetic proteins that comprise all T cell epitopes for said antigen. Preferably an adjuvant is covalently attached to a synthetic protein to yield a synthetic vaccine. The invention is exemplified
10 mainly by using HPV directed immunity as a model. However, the invention should not be read as being limited to HPV but rather as being relevant for a wide variety of immune related or relatable diseases.

Background of the invention

15 HPV infection is highly prevalent among young, sexually active male and female individuals. Large prospective studies showed that acquisition of HPV from male partners is common, occurring in 40-60% of subjects during a 3 year follow-up period (Koutsky et al., Am J Med 102 (5a) 3, 1997, Ho et al., N Eng J Med 338 (7) 1998,
20 Marrazzo et al., Am J Obstet Gynecol 183(3), 2000). Therefore, HPV is probably the most common sexually transmitted disease. Papillomaviruses of the high-risk types (e. g. HPV-16,-18, -31, -33 and -45) are responsible for cervical cancer (Bosch et al., Natl Cancer Inst 87, 1995, Zur Hausen, Bioch Biophys Acta 1288, F55 1996). Following infection of the basal epithelial cells, the immediate HPV early genes E1, E2, E6 and E7
25 are expressed. Prolonged and elevated expression of the E6 and E7 oncoproteins is tightly associated with HPV-induced dysplasia and transformation into cervical carcinoma.

 The protective role of the immune system in the defense against HPV-related diseases and HPV-induced cancer in humans is suggested by the fact that compared to
30 normal controls, immunosuppressed renal transplant patients and patients infected with HIV display a 17-fold greater incidence of genital HPV infection (Matorras et al. Am J Obstet Gynecol 164, 42, 1991, Halpert et al., Obstet Gynecol 68(2) 1986). The diminished capacity of immunosuppressed individuals to resolve HPV infection

indirectly points towards a protective role of the immune system early in infection. A positive role for HPV-specific Th-immunity was suggested by the predomination of CD4⁺ T-cells in regressing genital warts (Coleman et al., J. Clin. Pathol., 102, 1994) as well as by the detection of delayed-type hypersensitivity responses to HPV16 E7 in the majority of subjects with spontaneous regressing CIN lesions (Hopfl et al., 18th int. Papillomavirus conference, pp 2000). Studies on HPV16-specific T-cell immunity in humans suggested that protective HPV16-specific immunity is characterized by a strong IFN-gamma and interleukin-5 associated Th1/Th2 type memory T helper-cell response reactive against the three HPV16 early proteins E2, E6 and E7 (de Jong et al., Cancer Res. 62, p 472-9, 2002; Welters et al., Cancer Res. 63, p 636-41, 2003). The majority of patients with HPV16-positive pre-malignant lesions or cervical carcinoma fail to induce this type of T-cell reactivity and the lack of T-cell help may explain the general absence of HPV16-specific CD8⁺ cytotoxic T lymphocytes in these patients (Ressing et al., Cancer Res. 56, 1996; Nimako et al., Cancer Res. 57, 1997). Importantly, studies on spontaneously induced protective immunity against papilloma viruses in beagles and rabbits corroborate our findings in that E2 and E6-specific T-cell responses peaked during the regression of virus-induced lesions (Moore RA, Virology 2003). Furthermore, the use of DNA-vaccines encoding the early antigens E2, E6 and E7 prevented persistent infection and associated epithelial dysplasia in these animal models (Han et al. 1999, Selvakumar et al., J Virol 69(1) 1995). These data indicate that immunity against E2, E6, and E7 can be effective as immunoprophylaxis of papillomavirus infection as well as therapeutically for HPV-induced lesions and cancer.

New insights in the molecular and cellular events leading to a successful attack of chronic viral infections or virus-induced tumors have emerged only recently. Full mobilization of lytic effector cells crucially depends on proper activation (maturation) of DC either by innate immunity triggers such as microbial ligands of Toll like receptors (TLR) and/or by triggers of adaptive immunity such as CD40 ligand (CD40L) on activated CD4⁺ T helper (Th) cells (Melief et al., Immunol Rev. 188, 2002). Because infection of epithelia by HPV16 is, at least initially, not accompanied with gross disturbance of this tissue and/or strong pro-inflammatory stimuli, a successful immune response is likely to depend on HPV16-specific CD4⁺ T-cell help. Rather than relying on poorly defined immune system triggers such as recombinant vectors and adjuvants without molecularly defined function, it is now possible to design entirely

synthetic vaccines that provide both the proper antigenic and accessory signals for induction of a full scale burst of effector T-cells as well as T-cell memory. The main hallmark of such vaccines is that they provide not only antigens that stimulate both CD4+ and CD8+ T cells but also contain compounds that closely mimic the most successful natural triggers of dendritic cell (DC) activation (Melief et al., Immunol. Rev. 188, 2002; Zwaveling J. Immunol. 169, 2002). For a clinically relevant approach of immunizing subjects, for instance against (Myco) bacterially and/or virally infected cells or tumor cells, and HPV in particular, it is preferred that both specific T-helper cells and CTL's are induced. We have already shown that immunization with minimal CTL epitopes results in protection against tumors in some models (Feltkamp et al. Eur. J. Immunol. 23, 1993, Kast et al. PNAS, 88(6) 1991) whereas, in other models, it can lead to tolerance or functional deletion of virus-and tumor-specific CTL that when otherwise induced are protective (Toes et al. PNAS 93(15) 1996, Toes et al., J Immunol 156(10), 1996). The occurrence of tolerance or functional deletion decreases the effects of vaccination significantly. Epitopes involved with this effect were therefore not suitable for immunization purposes. Processing of exogenous antigens for presentation by MHC class I molecules by cross-priming as well as by other mechanisms is now widely recognized second pathway of processing for presentation by MHC class I, next to the well known endogenous route (Jondal et al., Immunity 5(4) 1996, Reimann et al. Curr. Opin Immunol 9(4), 1997). The normal outcome of antigen processing via this pathway is CTL tolerance, unless APC activation by CD4+ T-cells takes place (Kurts et al., J Exp Med 186(12), 1997). Furthermore, in several studies with murine virus infections, a positive correlation was detected between the frequency of CTL precursors and protective immunity (Sedlik et al. J Virol 74(13) 2000, Fu et al., J Immunol 162(7) 1999). For an optimal induction of CTL, presentation of CTL epitopes preferably takes place at the surface of professional antigen presenting cells (APC's) such as dendritic cells (Mellman et al., Trends Cell Biol 8, 1998, Rodriguez et al. Nat Cell Biol 1, 1999). Whereas minimal CTL-epitopes can, without the need of processing by professional antigen presenting cells, be presented to T-cells by any somatic cell, proteins need to be taken up and processed by professional antigen presenting cell for an optimal presentation of CTL and Th-epitopes in MHC class I and MHC class II, respectively, can occur (Manca et al. J Acquir Immune Defic Syndr 7, 1994).

The use of proteins from biological sources, either natural sources or recombinant proteins expressed in a host system, allows for the use of both small and larger proteins, either in purified form or as crude preps for vaccination purposes and is routinely applied in the art of vaccination. However, the use of proteins or recombinant proteins from biological sources requires extensive purification and quality control. Inherently the production of proteins or recombinant proteins from biological sources is subject to biological variations, various contaminants and errors. Because of the inherent variability and unpredictability of biological sources, the high rate of mutations and epigenetic changes in cell lines, bacteria, viruses and vectors used, the threat of contamination with DNA, in particular viral or recombinant DNA, the safety and quality control requirements set by regulatory authorities such as the EMEA (European Medicines Evaluation Agency), the US FDA (Food and Drug Administration) or the Japanese Pharmaceutical and Food Safety Bureau of Ministry of Health, Labour and Welfare are extensive and extremely strict. Clinical validation and approval of preparations for vaccination by the medical authorities and mandatory use of GMP grade materials, equipment and procedures make the use of proteins and recombinant proteins from biological sources extremely laborious, risky, costly and generally unattractive.

WO 02/070006 demonstrates the use of medium-sized synthetic peptides of 22-45 amino acids, which combine CTL and T-helper epitopes and are sufficiently large to be taken up by a professional antigen presenting cell (APC). A problem associated with the use of small or medium sized synthetic peptides is their short half-life in vivo and rapid clearing from the bloodstream, limiting the overall effectiveness of the composition for vaccination or vaccine. Furthermore the short stretch of amino acids limits the number of available epitopes contained within the synthetic peptide. The use of a substantially larger, or even a full size protein, containing most or all available epitopes of a given protein for all HLA molecules of the subject to be immunized, would be highly preferable. The current state of the art permits the synthesis of synthetic peptides up to roughly 60 amino acids, depending on the amino acid content. Although much longer peptides can in theory be synthesized, yield and quality progressively reduce with increasing size of the peptide.

On the one hand, the use of a highly defined, tightly controlled and monitored chemical process to obtain synthetic proteins would circumvent the problems

associated with the use of proteins from biological sources. On the other hand however, the length-limitation on chemically synthesized peptides also limits their immunological effectiveness as vaccines. It is an object of the present invention to overcome these short-comings and to provide for immunologically effective proteinaceous vaccines that are produced by chemical synthesis.

Detailed description of the invention

10 Definitions

A synthetic or artificial peptide is defined herein as a chemically produced polymer of amino acids or polypeptide, produced by chemical synthesis of a polymer of the 20 naturally occurring amino acids linked via peptide bonds. A synthetic protein is defined as a fusion product of at least two or more synthetic peptides, ranging in length from 2 to 80 amino acids, that have been chemically synthesized. Ligation of two or more synthetic peptides yields a synthetic protein which may correspond to a part or the full length a naturally occurring protein and which may vary in length from approximately 80 amino acids to approximately 1000 amino acids, preferably from 85 to 400 amino acids and more preferably from 90 to 200 amino acids. In contrast, a natural or recombinant protein is defined as an enzymatically produced protein or polypeptide, enzymatically produced *in vivo* or *in vitro* by translation of a coding RNA template.

GMP-grade peptides are produced under Good Manufacturing Practice protocols wherein all steps in the procedure are standardized, fully documented and constantly monitored. The documentation system leads to batch records that are logical and easy to follow for auditing by authorities such as the FDA or EMEA and will facilitate quality control and monitoring required for approval and clinical use of the artificial protein.

GMP-grade proteins may be extensively tested before clinical use in a vaccine by the following non extensive list of techniques: Mass Spectrometric Analysis, Amino Acid Analysis (AAA), Peptide Sequencing, Reverse Phase-HPLC, Residual Organic Volatiles, Bacterial Endotoxin Evaluation, Bioburden Evaluation, Net Peptide Content by AAA, Counter Ion Content (such as acetate, trifluoroacetate, hydrochloride, etc.),

Secondary Counter Ion Content, Water Content, Mass Balance Calculation and additional tests may include Specific Rotation (identity), Capillary Zone Electrophoresis (purity), Titrations and other chemical and biological analysis techniques obvious to the skilled person.

5 Adjuvants may be added to the composition to enhance and stimulate an immune response to the synthetic proteins in the preparation for vaccination. The use of various adjuvants for vaccination purposes are known in the art, (*e.g.* Melief Immunol Rev 188, 2002; Zwaveling J.Immunol. 169, 2002). Particularly preferred adjuvants to be used with the synthetic proteins of the current invention are bacterial LPS, CpG DNA and
10 other Toll-like receptor activating adjuvants and dendritic cell stimulating adjuvants. In a more preferred embodiment of the invention the adjuvant used is recognized by a Toll-like-receptor (TLR) present on a professional antigen presenting cell. Various adjuvants recognized by TLR's are known in the art and include *e.g.* lipopeptides, lipopolysaccharides, peptidoglycans, lipoteichoic acids, lipoproteins (from
15 mycoplasma, mycobacteria or spirochetes), double-stranded RNA (poly I:C), unmethylated DNA, lipoarabinomannan, flagellin, CpG-containing DNA, and imidazoquinolines. Adjuvants may be administered with the antigen or physically attached to the antigen by chemical modification, synthesis, conjugation and other methods known in the art.

20 The synthetic proteins of the current invention may exhibit some sequence divergence from their naturally occurring counterparts. The term "sequence identity" means that two polypeptide sequences are identical (*i.e.*, on an amino acid-by-amino acid basis) over a window of comparison. The term "percentage of sequence identity" is calculated by comparing two optimally aligned sequences over the window of
25 comparison, determining the number of positions at which the identical residues occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity.

30 As applied to the peptides of the invention, the term "substantial identity" means that two peptide sequences, when optimally aligned, such as by the programs GAP or BESTFIT using default parameters, share at least 80 percent sequence identity, preferably at least 90 percent sequence identity, more preferably at least 95 percent

sequence identity or more (e.g., 99 percent sequence identity). GAP uses the Needleman and Wunsch global alignment algorithm to align two sequences over their entire length, maximizing the number of matches and minimizes the number of gaps. Generally, the GAP default parameters are used, with a gap creation penalty = 50
5 (nucleotides) / 8 (proteins) and gap extension penalty = 3 (nucleotides) / 2 (proteins). For nucleotides the default scoring matrix used is nwsgapdna and for proteins the default scoring matrix is Blosum62 (Henikoff & Henikoff, 1992).

Preferably, residue positions, which are not identical, differ by conservative amino acid substitutions. Conservative amino acid substitutions refer to the
10 interchangeability of residues having similar side chains. For example, a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine,
15 tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur-containing side chains is cysteine and methionine. Preferred conservative amino acids substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

20 Alignment and comparison of relatively short amino acid sequences (less than about 30 residues) is typically straightforward. Optimal alignment of sequences for aligning a comparison window may be conducted by the local homology algorithm of Smith and Waterman (1981) Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for
25 similarity method of Pearson and Lipman (1988) Proc. Natl. Acad. Sci. (USA) 85:2444, by computerised implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Version 10.2, Genetics Computer Group, 575 Science Dr., Madison, Wisconsin 53711, USA), or by inspection, and the best alignment (i.e., resulting in the highest percentage of sequence
30 similarity over the comparison window) generated by the various methods is selected.

Detailed description of the invention

In a first aspect the present invention therefore relates to a method for producing a synthetic protein. The synthetic protein preferably comprises an amino acid sequence that is at least 80, 85, 90, 95, 97, 98, 99 or 100% identical to at least 46 contiguous amino acids of a naturally occurring antigenic protein of a pathogen or tumor. The method of the invention comprises the steps of: (a) chemically synthesizing two or more fragments each consisting of 2 – 80 contiguous amino acids of the amino acid sequence, whereby in the amino acid sequence the two or more fragments are neighbouring and non-overlapping; (b) chemically ligating the C-terminus of a fragment to the N-terminus of a neighbouring fragment to produce the synthetic protein or a part thereof; (c) optionally, repeating step C to sequentially ligate a further neighbouring fragment obtained from step C or step B to produce the synthetic protein.

Preferably, the synthetic protein comprises an amino acid sequence that is at least 80, 85, 90, 95, 97, 98, 99 or 100% identical to at least 46, 47, 48, 50, 55, 60, 70 or 80 contiguous amino acids of a naturally occurring antigenic protein of a pathogen or tumor. More preferably, the synthetic protein comprises amino acid sequence that is at least 80, 85, 90, 95, 97, 98, 99 or 100% identical to the entire (i.e. full-length) amino acid sequence of the naturally occurring antigenic protein of a pathogen or tumor. A preferred naturally occurring antigenic protein is an HPV protein, more preferably an HPV E2, E6 or E7 protein and even more preferably the naturally occurring HPV protein is an HPV16, -18, -31, -33 or -45 protein, of which HPV16 and HPV18 proteins are most preferred. Thus, the synthetic proteins employed in the subject invention need not be identical, but may be substantially identical, to the naturally occurring antigenic protein of a pathogen or tumor. As such the synthetic proteins may be subject to various changes, such as insertions, deletions, and substitutions, either conservative or non-conservative, where such changes might provide for certain advantages in their use. Likewise, the HPV-derived synthetic proteins of the invention can be modified in a number of ways whereby the proteins preferably comprise a sequence substantially identical (as defined above) to an amino acid sequence of at least one of the HPV-derived antigenic sequences selected from SEQ ID NO's 1 – 6, while maintaining at least 80, 85, 90, 95, 97, 98, 99 or 100% sequence identity with one of SEQ ID NO's 1 - 6.

In the method of the invention, larger synthetic proteins may be synthesized by the sequential ligation of synthetic peptides as disclosed in this application. Preferably in this method in a first step a synthetic peptide is immobilized on a substrate. In subsequent steps a second and optionally more synthetic peptides are covalently
5 attached to the peptide or fused peptides on the support by chemical means. In the examples a similar strategy is followed for the chemical synthesis of other highly immunogenic HPV proteins. The E6 proteins of HPV16 and HPV18 can be conveniently synthesized from 4 artificial peptides (example numbers 2 and 5). For the larger E2 protein of HPV16 and HPV18 two different strategies are provided by the
10 current invention as a non-limiting example to illustrate the flexibility of the method (example numbers 3 and 6). Choosing suitable alternatives to ensure efficient linkage of individual peptides to obtain an artificial protein can circumvent sequence specific difficulties.

In a preferred embodiment the neighbouring non-overlapping fragments (i.e. the
15 individual synthetic peptides that are used as building blocks for the synthesis of the synthetic protein by chemical ligation) are selected to comprise a N-terminal cysteine or glycine residue. The individual neighbouring non-overlapping fragments to be synthesized are preferably of moderate length (from 20 to 80 amino acids, preferably up to about 65 amino acids, more preferably up to 55 amino acids in length, more
20 preferably up to 45 amino acids in length, most preferably up to 35 amino acids in length), and are preferably synthesized as their thio-ester by normal solid phase peptide synthesis, e.g. by Fmoc-based or Boc-based chemistry, on a normal solid support, e.g. on polystyrene based or polystyrene/polyethyleenglycol-copolymer based material containing a proper handle, e.g. a safety catch handle, in acceptable purity, e.g.
25 preferably more than 80 % pure. Preferably no building blocks with carboxy-terminal proline (P) are used since coupling to proline thioesters is cumbersome. In case the protein to be synthesized does not contain naturally occurring cysteines that are compatible with the preferred embodiment, e.g. because cysteines are too far apart in the sequence, it is preferred to apply a modified ligation strategy in which one or more
30 building blocks are used with an amino-terminal glycine (G). The N-terminal G can then be modified with a protection/activation group like the N-2,3,4-trimethoxy-5-mercaptophenyl group which provides the glycine a reactivity towards thio esters that

is comparable with that of a cysteine and still yields a glycine in the endproduct (J. Am. Chem. Soc. 124, 4642 (2002)).

The current invention is also highly suited for the production of highly toxic or unstable proteins. The described method may offer an alternative for the production of proteins, which are currently difficult to produce by recombinant technology due their inherent toxicity (e.g. HPV16 E2, wild-type p53) or their instability in vivo in the bacterial/viral/eukaryote expression systems.

In vivo injected proteins are often rapidly degraded by exopeptidases present in the extracellular matrix. In a preferred embodiment of the current invention such degradation can be overcome by protein modification like the introduction of D-amino acids at the N- and C-termini and at strategic sites within the protein sequence. In addition proteins can be made more stable towards enzymatic degradation by introduction of non-natural amino acids at particular sites within the sequence. For instance non-natural amino acids can be various forms of synthetic α -amino acids, synthetic β amino acids and/or N-methylated synthetic amino acids, features that cannot be easily achieved by conventional in vivo methods for production of proteins.

The remarkably enhanced immunogenic activity of the synthetic E7 protein compared to minimal (9 AA) or longer (35 AA) synthetic peptides is also at least in part due to the enhanced stability in vivo of a synthetic protein. This is illustrated by the fact that in contrast to synthetic E7 protein, vaccination with an equimolar dose of long E7 peptide was not efficient in the induction of CD8⁺ IFN γ -producing HPV16 E7-specific T-cells and this was reflected in the lack of protection against a tumour challenge. However, vaccination with a ~8 fold higher dose of long peptide did result in a strong E7-specific T-cell response and tumour protection. The use of larger or full length (as compared to the naturally expressed counterpart of a protein) synthetic proteins or the use of specific domains, chemical modifications, removal of targeting signals for degradation from synthetic proteins, are technical measures which will help to design synthetic proteins that exhibit an enhanced half-life *in vivo*. Synthetic proteins with an enhanced stability are more potent inducers of an immunogenic response. The enhanced immunogenic activity, i.e. more effective in prophylactic and therapeutic tests in mice on an equimolar basis of the synthetic protein vaccine as compared to short synthetic peptides, is at least partly explained by a less rapid degradation of larger proteins and a decreased or delayed clearing from the

bloodstream. After partial degradation and partial proteolysis, the remaining fragments of the larger synthetic protein may still be sufficiently large to be taken up by professional antigen presenting cells and elicit a vigorous immune response.

The (poly)peptides that are chemically ligated to form the synthetic proteins of the invention may be modified to provide a variety of desired attributes, e.g., improved pharmacological characteristics, while increasing or at least retaining substantially all of the biological activity of the unmodified peptide. For instance, the peptides can be modified by attachment of adjuvants, enhancing the stability or aid in the fusion process of synthetic peptides, enhance immunological properties by altering, extending, decreasing the amino acid sequence of the protein. Substitutions with different amino acids or amino acid mimetics can also be made.

The individual residues of the immunogenic protein derived synthetic protein of the invention can be incorporated in the synthetic protein by a peptide bond or peptide bond mimetic. A peptide bond mimetic of the invention includes peptide backbone modifications well known to those skilled in the art. Such modifications include modifications of the amide nitrogen, the α -carbon, amide carbonyl, complete replacement of the amide bond, extensions, deletions or backbone cross-links. See, generally, Spatola, Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. VII (Weinstein ed., 1983). Several peptide backbone modifications are known, these include, ψ [CH_2S], ψ [CH_2NH], ψ [CSNH_2], ψ [NHCO], ψ [COCH_2] and ψ [(E) or (Z) $\text{CH}=\text{CH}$]. The nomenclature used above, follows that suggested by Spatola, above. In this context, ψ indicates the absence of an amide bond. The structure that replaces the amide group is specified within the brackets.

Amino acid mimetics may be incorporated in the synthetic proteins. An "amino acid mimetic" as used here is a moiety other than a naturally occurring amino acid that conformationally and functionally serves as a substitute for an amino acid in a peptide of the present invention. Such a moiety serves as a substitute for an amino acid residue if it does not interfere with the ability of the peptide to elicit an immune response against the relevant epitopes, such as e.g. an HPV-derived epitope. Amino acid mimetics may include non-protein amino acids, such as β -, γ -, δ -amino acids, β -, γ -, δ -imino acids (such as piperidine-4-carboxylic acid) as well as many derivatives of L- α -amino acids. A number of suitable amino acid mimetics are known to the skilled artisan, they include cyclohexylalanine, 3-cyclohexylpropionic acid, L-adamantyl

alanine, adamantylacetic acid and the like. Peptide mimetics suitable for peptides of the present invention are discussed by Morgan and Gainor, (1989) *Ann. Repts. Med. Chem.* 24:243-252.

In another preferred embodiment of the method of the invention, the synthetic
5 protein is chemically conjugated to an adjuvant. A preferred adjuvant is a chemically synthesized adjuvant. The conjugation of (synthetic) adjuvants to antigens is known in the art (Shirota et al., 2000. *J. Immunol.* 164:5575, Cho, H. J., K., et al, 2000. *Nat. Biotechnol.* 18:509, Tighe, H., K. et al., 2000. *J. Allergy Clin. Immunol.* 106:124. Tighe, H., K. et al., 2000. *Eur. J. Immunol.* 30:1939.)

10 It is also known in the art mentioned above that conjugation of antigens to adjuvants that are able to specifically activate professional antigen presenting cells such as e.g. dendritic cells via e.g. TOLL-like receptors, are superior vaccines compared to those in which both components are mixed together. In one embodiment adjuvants, preferably synthetic adjuvants, are conjugated to the synthetic proteins of the current
15 invention, resulting in a purely synthetic and thereby completely chemically defined composition for vaccination purposes.

One suitable technology for conjugating biomolecules is known in the art as "click chemistry". In this technology an azide moiety in one molecule is reacted with an alkyne group in another molecule in order to produce a conjugate wherein both
20 molecules are covalently connected via a 1,2,3-triazole ring. The reaction is orthogonal to virtually all reactive groups normally present in biomolecules, is catalyzed by Cu(I) ions and can be performed in aqueous media at relative moderate reaction conditions; references Kolb H.C. et al., *Angew. Chem. Int. Ed.* 40, 2004-2021 (2003) and Wang, Q. et al., *J. Am. Chem. Soc.* 125, 3192-3193 (2003). However, other means for
25 conjugating biomolecules and that are applicable to the antigens and adjuvants of the present invention are well known in the art.

Preferred adjuvants for combination with and/or conjugation to the antigens of the present invention are adjuvants that stimulate professional antigen presenting cells, such as dendritic cells. Such adjuvants preferably are recognized by Toll Like
30 Receptors (TLR's) and are known in the art to include e.g. lipopeptides, lipopolysaccharides, peptidoglycans, lipoteichoic acids, lipoproteins (from mycoplasma, mycobacteria or spirochetes), double-stranded RNA (poly I:C),

unmethylated DNA, lipoarabinomannan, flagellin, CpG-containing DNA, and imidazoquinolines.

In one preferred embodiment of the current invention, CpG DNA is used as a TLR activating adjuvant and covalently attached to the N and/or C termini or to specific amino acids of a synthetic protein. CpG DNA and analogues thereof are known to be potent activators of TLR9. The method of conjugation of CpG to proteins is described extensively in the references (Shirota et al., 2000. *J. Immunol.* 164:5575, Cho, H. J., K., et al, 2000. *Nat. Biotechnol.* 18:509, Tighe, H., K. et al., 2000. *J. Allergy Clin. Immunol.* 106:124. Tighe, H., K. et al., 2000. *Eur. J. Immunol.* 30:1939.).

10 A nucleophilic group like a thiol group in one of the molecules can be reacted with an electrophilic group like a haloacetyl group or a maleimido group in the other molecule. Alternatively an amine group in one of the molecules can be reacted with an activated carboxylic acid group, like a hydroxysuccinimide ester, in the other molecule. An amine group in one of the molecules can also be reacted with an amine group in the

15 other molecule by reaction with a bifunctional crosslinker like gluteraldehyde. (Drijfhout, J.W. and Hoogerhout, P in W.C. Chan and P.D. White, Chapter 10. Oxford University Press 2000).

Also polyIC, acting upon TLR3, may be covalently attached to the synthetic proteins of the current invention. PolyIC (polyinosinic:polycytidylic acid) is a "mimic" of double-stranded viral RNA and induces interferon. As such it can be used as adjuvant in vaccination (Monshouwer M. et al., *Biochem. Pharmacol.* 52, 1195-1200 (1996) and Moriyama H, et al., *Proc. Natl. Acad. Sci. USA* 99, 5539-5544 (2002). PolyIC may also be covalently attached to a synthetic protein via the methods described in references (Shirota et al., 2000. *J. Immunol.* 164:5575, Cho, H. J., K., et al, 2000. *Nat. Biotechnol.* 18:509, Tighe, H., K. et al., 2000. *J. Allergy Clin. Immunol.* 106:124. Tighe, H., K. et al., 2000. *Eur. J. Immunol.* 30:1939.).

20

25

Imiquimod and analogues, acting upon TLR7 and 8, and Pam3Cys, acting upon TLR2, may also be advantageously used, alone or in combination with other synthetic adjuvants for conjugations to the synthetic proteins according to the current invention.

30 Pam3Cys is a compound in which 3 palmitic acid units are bound to a cystein via a glycerol molecule and is a potent adjuvant (Rabanal, F., et al., *J. Chem. Soc, Perkin Trans. 1*, 945-952 (1991) and Metzger J.W. et al., *Biochim. Biophys. Acta*, 1149, 29-39 (1993).

In a further preferred embodiment the method comprises the step of formulating the synthetic protein into a pharmaceutical composition by mixing the protein with a pharmaceutically acceptable carrier as defined below. In one aspect the invention thus also relates to a method for producing a pharmaceutical composition comprising the synthetic proteins of the invention. The method comprises at least the steps of mixing
5 synthetic proteins of the invention obtained in the methods described above with a pharmaceutically acceptable carrier and further constituents like adjuvant as described above and below.

In a further aspect the invention relates to a composition comprising a synthetic
10 protein obtained in a method described above. The synthetic protein preferably is as defined above. The compositions comprising synthetic proteins as obtained by chemical synthesis in the methods of the invention have several advantages over conventional compositions comprising antigenic proteins obtained from biological systems. Inherently processes for producing proteins in biological systems are subject
15 to biological variation. In addition to this variation, there is the inherent risk that components isolated from biological sources, be it from recombinant hosts, non-GMO or even cell-free systems, may be contaminated with other biomolecules from the biological production system some of which may be very harmful. In contrast, the compositions of the invention are substantially free of biological contaminants.

20 Preferably, the compositions are free biological contaminants to the extent that the level of such contaminants is below the detection level of available assays. The biological contaminants that are absent from the compositions include any biomolecule from the production organism or system. Such contaminants thus include proteins, carbohydrates, nucleic acids including DNA and RNA, lipids and combinations thereof
25 such as e.g. bacterial endotoxins, and may even include viruses that can infect humans. Preferably, the compositions are substantially free of contaminants (biomolecules) from the organism or virus from which the naturally occurring protein is derived, i.e. in which the protein occurs naturally, or alternatively, in which the protein is produced in case of recombinant production. A major problem is the potential contamination of the
30 proteinaceous preparation with nucleic acids, in particular pathogenic and/or oncogenic nucleic acids such as e.g. viral and/or recombinant nucleic acids. The compositions comprising the synthetic proteins according to the current invention are thus essentially free of nucleic acid contamination, more in particular free of viral and/or oncogenic

nucleic acids, of which in particular DNA. Contamination of nucleic acids and in particular of viral and/or oncogenic nucleic acids, more in particular of HPV nucleic acids can be demonstrated by PCR amplification techniques known in the art (Ausubel et al., Current protocols, 1989). Preferably, the composition comprises a synthetic protein (the protein e.g. comprising an amino acid sequence that is at least 80% identical to at least 46 contiguous amino acids of a naturally occurring antigenic protein of a pathogen or tumor), whereby the composition is free of a nucleic acid encoding the amino acid sequence of the synthetic protein. The compositions comprising synthetic proteins according to the current invention preferably do not display detectable DNA contamination when assayed by PCR amplification with primers suitable for amplification of viral and/or oncogenic nucleic acids after 30 cycles, more preferably after 40 cycles and most preferably after 50 cycles of PCR amplification. More preferably, the compositions are free of HPV nucleic acid (DNA) fragments as detectable by 30, 40 or 50 cycles of PCR amplification with suitable HPV specific primers. Most preferably, the composition is substantially free of DNA encoding the amino acid sequences of SEQ ID NO.'s 1-6.

A further preferred composition comprises an adjuvant. The adjuvant preferably is an adjuvant that is capable of activating dendritic cells. More preferably the adjuvant is an adjuvant that is capable of activating a TLR, such as defined above. The composition may comprise an adjuvant mixed with the synthetic protein or it may contain an adjuvant that is covalently conjugated to the protein or it may contain both. Moreover more than one adjuvant may be present. A number of adjuvants are well known to one skilled in the art. Suitable adjuvants include incomplete Freund's adjuvant, alum, aluminum phosphate, aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn -glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL+TDM+CWS) in a 2% squalene/Tween 80 emulsion. The effectiveness of an adjuvant may be determined by measuring the amount of antibodies directed against the immunogenic peptide. A particularly useful adjuvant and immunisation schedule are described in Kwak et al. New Eng. J. Med. 327-1209-1215 (1992). The

immunological adjuvant described there comprises 5% (wt/vol) squalene, 2.5% Pluronic L121 polymer and 0.2% polysorbate in phosphate buffered saline. In a preferred embodiment of the invention an adjuvant is recognized by a Toll-like-receptor (TLR) present on antigen presenting cells, i.e. the adjuvant is a TLR-ligand.

5 Various adjuvants recognized by TLR's are described above and may be used for mixing with and/or conjugation to the synthetic proteins of the invention.

Most preferably the adjuvant is a synthetic adjuvant which is chemically synthesized rather than purified from a biological source. In the most preferred embodiment of the current invention synthetic proteins are conjugated to a (one or
10 more) synthetic TLR recognizable adjuvant(s), which forms the basis for a completely defined and synthetic composition for vaccination. Yet a further preferred composition comprises an anti-CD40 antibody.

The compositions of the invention further comprises a pharmaceutically acceptable carrier. The pharmaceutical compositions (for vaccination) are intended for
15 parenteral, oral, transdermal or transmucosal administration. The pharmaceutical compositions may be administered parenterally, e.g., subcutaneously, intradermally, or intramuscularly. Thus, the invention provides compositions for oral or preferably parenteral administration, which comprise a solution of the immunogenic synthetic proteins or synthetic vaccines dissolved or suspended in an acceptable carrier,
20 preferably an aqueous carrier. A variety of aqueous carriers may be used, e.g., water, buffered water, 0.4% saline, 0.3% glycine, hyaluronic acid and the like. These compositions may be sterilized by conventional, well-known sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile solution prior
25 to administration. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as buffering agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, and triethanolamine oleate.

30 For solid compositions, conventional nontoxic solid carriers may be used which include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. For oral administration, a pharmaceutically acceptable nontoxic

composition is formed by incorporating any of the normally employed excipients, such as those carriers previously listed, and generally 10-95% of active ingredient, that is, one or more synthetic proteins of the invention, and more preferably at a concentration of 25%-75%. As noted above, the compositions are intended to induce an immune response to the synthetic proteins. Thus, compositions and methods of administration suitable for maximizing the immune response are preferred. For instance, synthetic proteins may be introduced into a host, including humans, linked to a carrier or as a homopolymer or heteropolymer of active protein units. Useful carriers are well known in the art, and include, e.g., thyroglobulin, albumins such as human serum albumin, tetanus toxoid, polyamino acids such as poly(lysine:glutamic acid), influenza, hepatitis B virus core protein, hepatitis B virus recombinant vaccine and the like. Alternatively, a "cocktail" of synthetic proteins can be used, comprising a selection of immunogenic HPV synthetic proteins, such as E7, E6 and E2 or parts thereof and their conjugates with adjuvants. A mixture of more than one synthetic protein has the advantage of increased immunological reactions.

The concentration of immunogenic synthetic proteins of the invention in the pharmaceutical formulations can vary widely, i.e. from less than about 0.1%, usually at or at least about 2% to as much as 20% to 50% or more by weight, and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.

Further guidance regarding formulations that are suitable for various types of administration can be found in *Remington's Pharmaceutical Sciences*, Mace Publishing Company, Philadelphia, PA, 17th ed. (1985). For a brief review of methods for drug delivery, see, Langer, Science 249:1527-1533 (1990). E.g. transdermal delivery systems include patches, gels, tapes and creams, and can contain excipients such as solubilizers, permeation enhancers (e.g. fatty acids, fatty acid esters, fatty alcohols and amino acids), hydrophilic polymers (e.g. polycarbophil and polyvinyl pyrillidine and adhesives and tackifiers (e.g. polyisobutylenes, silicone-based adhesives, acrylates and polybutene). Transmucosal delivery systems include patches, tablets, suppositories, pessaries, gels, and creams, and can contain excipients such as solubilizers and enhancers (e.g. propylene glycol, bile salts and amino acids), and other vehicles (e.g. polyethylene glycol, fatty acid esters and derivatives, and hydrophilic polymers such as hydroxypropylmethyl cellulose and hyaluronic acid). Injectable delivery systems

include solutions, suspensions, gels, microspheres and polymeric injectables, and can comprise excipients such as solubility-altering agents (e.g. ethanol, propylene glycol and sucrose) and polymers (e.g. polycaprylactones, and PLGA's). Implantable systems include rods and discs, and can contain excipients such as PLGA and polycapryl lactone. Other delivery systems that can be used for administering the pharmaceutical composition of the invention include intranasal delivery systems such as sprays and powders, sublingual delivery systems and systems for delivery by inhalation. For administration by inhalation, the pharmaceutical compositions of the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurised packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurised aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the peptides of the invention and a suitable powder base such as lactose or starch. The pharmaceutical compositions of the invention may be further formulated for administration by inhalation as e.g. described in U.S. Patent No. 6,358,530. A preferred composition of the invention is a composition for use as a vaccine.

In yet another aspect the invention relates to a method for the treatment or prevention of a tumor or an infectious disease, whereby the method comprises the administration to a subject of a synthetic protein produced as defined above or a composition as defined above, in a therapeutically effective amount. Thereby the synthetic protein comprises an amino acid sequence of a naturally occurring antigenic protein of the tumor or infectious agent as defined above. A preferred method is a method for the treatment or prevention of an HPV-associated disease, including prevention or treatment of HPV infection, particularly genital infection, prevention or regression of HPV virus-induced lesions such as genital warts and epithelial dysplasia, and particularly including the prevention and treatment HPV-induced dysplasia and transformation into cancer, in particular cervical cancer, anogenital cancer or head- and neck-cancer, and other HPV-induced cancers.

For those jurisdictions where methods of treatment are unpatentable by law, the invention likewise pertains to the use of a synthetic protein produced as defined above,

or the use of a composition as defined above, for the manufacture of a medicament for (use in a method for) the treatment or prevention of a tumor or an infectious disease as defined above.

The invention thus relates to the use of synthetic proteins and synthetic compositions for vaccination in a method for vaccination of a subject. Preferably the method of vaccination is directed against HPV, more preferably against the oncogenic types HPV 16, 18, 31, 33 and 45. The method comprises administering to the subject a pharmaceutical composition comprising a synthetic protein as defined above. In a preferred method, the pharmaceutical composition also comprises a TLR activating adjuvant, preferably a synthetic adjuvant and more preferably conjugation of the synthetic adjuvant to the synthetic protein of the invention.

In another aspect, the invention relates to the use of a HPV-derived antigenic synthetic protein as defined above for the manufacture of a vaccine or composition for vaccination, aimed at prophylaxis and/or therapy of HPV infection in a subject. Preferably, the vaccine is a pharmaceutical composition suitable for oral, parenteral, transdermal or transmucosal administration.

Pharmaceutical (vaccine) compositions comprising at least one synthetic protein of the invention are also an embodiment of the invention. The synthetic proteins of the present invention and pharmaceutical compositions thereof are useful for administration to mammals, particularly humans, to treat and/or prevent disease as indicated above. Suitable formulations are found for instance in Remington's Pharmaceutical Sciences, Mack Publishing Company, Philadelphia, Pa., 17th ed. (1985), which is well known in the art and may easily be adapted by a skilled artisan.

The immunogenic synthetic proteins of the invention are administered prophylactically or to an individual already suffering from the disease. The compositions are administered to a patient in an amount sufficient to elicit an effective immune response. An amount adequate to accomplish this is defined as "therapeutically effective dose" or "immunogenically effective dose." Amounts effective for this use will depend on, e.g., the peptide composition, the manner of administration, the stage and severity of the disease being treated, the weight and general state of health of the patient, and the judgement of the prescribing physician, but generally range for the initial immunisation (that is for therapeutic or prophylactic administration) from about 0.1 µg to about 50 µg per kilogram (kg) of body weight per patient, more commonly

from about 1 µg to about 20 µg per kg of body weight. Boosting dosages are typically from about 1 µg to about 20 µg per kg of body weight, using a boosting regimen over weeks to months depending upon the patient's response and condition. A suitable protocol would include 3-4 priming injections at three weeks intervals, eventually followed by booster injections at regular intervals (e.g. 6 months).

The following non-limiting Examples describe the preparation of HPV-derived antigenic synthetic proteins of the invention.

Description of the Figures

- 10 Figure 1: Synthetic scheme for the synthesis of the HPV16-E7 protein.
Figure 2: Maldi-tof mass spectrum of purified synthetic HPV16-E7 protein.
Figure 3: A single injection of 4.5 nmol synthetic HPV16-E7 protein results in the induction of high numbers of HPV16-E7₄₉₋₅₇-specific CD8⁺ T-cells. C57BL/6 mice were injected sub-cutaneously with the indicated antigens at equimolar concentrations of the minimal CTL epitope (E7₄₉₋₅₇) mixed with CpG, with 150 µg of E7₄₃₋₇₇ (high dose) peptide+CpG which served as positive control, or not vaccinated (naïve). The percentage of spleen-derived CD8⁺ T-cells stained with H-2D^b-E7₄₉₋₅₇ PE-conjugated tetramers (TM) is shown directly ex-vivo (A) or following one round of in vitro stimulation (B). Bars indicate the mean percentage of three mice and SEM.
- 20 Figure 4: Vaccination with synthetic HPV16-E7 protein induces functional IFN γ -producing CD8⁺ T-cells. Spleen cell cultures were stimulated with the dendritic cell line D1 only or D1 cells pulsed with the E7₄₃₋₇₇ peptide or D1 pulsed with recombinant HPV16-E7 protein and analyzed by intracellular cytokine staining on a flow cytometer. Three mice injected with the synthetic HPV16-E7 protein are shown in combination with a representative example of mice injected with an equimolar concentration of recombinant HPV16-E7 or a high dose of peptide E7₄₃₋₇₇ and a non-vaccinated (naïve) mouse.
- 25 Figure 5:
a) Groups of mice were vaccinated at day -28 and day -14 with 4.5 nmol of synthetic E7 protein (n=10) and equimolar amounts of recombinant E7 protein (n=9) or long peptide admixed with 50 µg CpG (peptide low dose, n=10) or with PBS only (naïve, n=7). As a control the long peptide was also used at an approximately 8-fold higher dose (n=5) which was previously established to be protective in 80% of mice. At day
- 30

0, 50.000 TC-1 tumour cells were s.c. injected at the contralateral side and tumour growth was monitored every 2-3 days up to 100 days and survival curves were plotted.

- b) Mice challenged with TC-1 tumour cells were vaccinated at the contralateral side with indicated vaccines (n=8 per group) when tumours were palpable at day 9 and
5 boosted at day 23 (arrows). Tumour growth was monitored until day 95 and survival curves were plotted.

Examples

10 Example 1: Chemical synthesis of HPV16 E7 peptides and ligation of peptides

Chemical synthesis of HPV 16 E7 peptides and protein

- The homogeneous synthetic E7 protein was prepared by chemical ligation of two oligopeptides assembled separately by Fmoc solid phase synthesis. The N-terminal 60-
15 meric segment of E7 was prepared on sulphonamide safety-catch resin and converted into thioester 1 [E7 (1-60)] according to a published procedure (Ingenito, R et al., *J. Am. Chem. Soc.* **121**, 11369-11374 (1999). The C-terminal 38-meric carboxamide [E7(61-98), 2] was produced via a standard Fmoc solid phase protocol. Subsequently, the RP-HPLC purified fragments 1 and 2 were ligated to give the full-length E7 protein (3). The ligation reaction could be successfully conducted using thiophenol/benzyl
20 mercaptane as additives according to the one of the original native ligation procedures (Hackeng T.M., et al, *Proc. Natl. Acad. Sci. USA* **96**, 10068-10073 (1999) and Dawson, P.E., et al., *J. Am. Chem. Soc.* **119**, 4325-4329 (1997). We found, however, mercaptoethyl sulphonic acid sodium salt (Flavell R.R., et al., *Org. Lett.* **4**, p165-168 2002) to be a more convenient additive as it gave a homogeneous and odourless
25 reaction mixture.

- The following essential modifications were introduced to the overall synthetic pathway in order to obtain an acceptable yield of the protein. First, it proved to be necessary to include 20 mM EDTA into the ligation buffer to prevent complete and irreversible precipitation of the product/reaction intermediates. We have also found that
30 the preparative purification of the E7 protein could not been done with RP HPLC because of the poor yield over this step. A satisfactory purification protocol comprises gel filtration of the reaction mixture over Superdex 75 column under strongly denaturing conditions (6M guanidine hydrochloride) followed by dialysis of the pooled

fractions containing the target protein against water. It has to be noted that gel filtration step performed under non-denaturing (phosphate buffer) or weakly denaturing (7 M urea) condition yielded the product still contaminated with E7(61-98) presumably because of co-aggregation of the latter fragment and full-length E7. These results are fully consistent with the well known (Alonso, L.G., et al., *Biochemistry*, **41**, 10510-10518 (2002) aggregation potential of E7 and the reported observation that it is the C-terminal part of E7 which is responsible for the oligomerization of the protein (Clemens, K.E., et al., *Viol.* **214**, 289-293 (1995).

Experimental

10 Peptide synthesis - Fragments E7(1-60) thioester (1) and E7(61-98) C-terminal carboxamide (2) were prepared by Fmoc-SPPS with PyBOP activation on a 0.25 mmol scale using ABI 433A instrument. An *in situ* protocol suggested in (Han, Y.X., et al., *J. Org. Chem.* **62**, 4307-4312 (1997) in order to minimize racemisation of the Cys residues was used. Each synthetic cycle comprised a Fmoc removal with 20% piperidine in NMP, a NMP wash, a 1 h PyBOP assisted coupling step with 1 mmol of a Fmoc-amino acid in the presence of 2 mmol of DIPEA, second NMP wash, Ac₂O/DIPEA capping step and, finally, a NMP wash.

15 Peptide thioester E7(1-60) (1) - Fragment 1 was assembled starting from 4-sulfamylbutyryl AM resin (Novabiochem). The N-terminal methionine residue was introduced as Boc-Met-OH. The thioester was generated from the immobilised and protected oligopeptide. Briefly, the resin was alkylated with TMSCHN₂ and the peptide was cleaved with ethyl 3-mercaptopropionate in the presence of NaSPh and deprotected with TFA/ethyl 3-mercaptopropionate/TIS/m-cresol/H₂O 96/1.2/1.2/0.8/ 0.8.

20 Peptide amide E7(61-98) (2) - Fragment 2 was assembled on RAM Tentagel resin (Rapp Polymere). Upon the completion of the chain assembly the peptide was deprotected and cleaved from the resin by 2 h treatment with a cleavage mixture (TFA/EDT/TIS/m-cresol/H₂O 96/1.2/1.2/0.8/0.8) as described (Dick, F. in *Methods in Molecular Biology, Vol. 35: Peptide Synthesis Protocols* pp. 63-72. (Eds. Pennington, M. W.& Dunn, B. M.) (Humana Press Inc., Totowa, NJ, 1994)).

30 Ligation to obtain full-length E7-protein (3)

Method A Peptide thioester 1 (22 mg, 3.1 µmol) was mixed with peptide 2 (11.3 mg, 2.7 µmol) and dissolved in 3.0 mL buffer (100 mM phosphate, 20 mM EDTA, 6 M Gdn•HCl, pH 8). Subsequently, 60 µL thiophenol and 60 µL benzyl mercaptane were

added and the mixture was stirred for 65 h at 22 °C. The mixture was treated with 100 mg DTT and loaded on Superdex 75 HL 16/60 column (Pharmacia) equilibrated in 25 mM Na₂HPO₄, 25 mM NaH₂PO₄, 5 mM EDTA, 5 mM DTT, pH 7. The product eluting at 37 mL (1 mL/min) was collected and repurified by RP HPLC (Vydac C-4 214TP510 column; 250x10 mm, 5 mL/min) eluting with a gradient of acetonitrile in 0.1 % aq. TFA) to give 0.6 mg (yield 2 %) of homogeneous E7-protein as determined by mass-spectroscopy, RP HPLC and quantitative amino acid analysis. Electrospray ionisation MS was performed on PE Sciex API 165 single quadrupole mass spectrometer. Matrix-assisted laser-desorption ionization (MALDI) MS-spectra were recorded on a Voyager-DE PRO instrument using α -cyano-4-hydroxycinnamic acid as a matrix.

Method B Peptide thioester 1 (10.5 mg, 1.4 μ mol) was mixed with peptide 2 (16 mg, 2 μ mol) and dissolved in 1.8 mL of the ligation buffer (200 mM phosphate, 20 mM EDTA, 6 M guanidine hydrochloride, 75 mM MesNa, pH 8.5) and the mixture was stirred for 65 h at 22 °C. and then loaded on Superdex 75 HL 16/60 column (Pharmacia) equilibrated in the purification buffer (6 M guanidine hydrochloride, 25 mM Na₂HPO₄, 25 mM NaH₂PO₄, 5 mM EDTA, 5 mM DTT, pH 7) and eluted at 0.8 mL/min. The product eluting at 50 mL was collected (5.5 mL) and dialyzed into water using dialysis tubing with 3kD cut-off (2 L water, changed 3 times over 40 h) to give 7.5 mL of a solution containing 6.7 mg (yield 44 %) of E7 protein. The chromatographic, spectroscopic and immunogenic properties of this material were indistinguishable from the protein obtained by method A.

Example 2: Chemical synthesis of HPV16 E6

HPV16-E6 PROTEIN SEQUENCE

```

001 MHQKRTAMFQ DPQERPRKLP QLCTELQTTI HDIILECVYC KQQLLRREVEY DFAFRDLCIV
061 YRDGNPYAVC DKCLKFYSKI SEYRHYCYSL YGTTLQQQYN KPLCDLLIRC INCQKPLCPE
121 EKQRHLDDKKQ RFHNIRGRWT GRCMSCCRSS RTRRETQL

```

Four fragments selected for peptide synthesis to obtain full length HPV16E6 synthetic protein:

```

01:      001-039 MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVY-SR
02:      040-072 X-CKQQLLRREVEYDFAFRDLCIVYRDGNPYAVCDK-SR
03:      073-117 X-CLKFYISKISEYRHYCYSLYGTTLQQQYNKPLCDLLIRINCQKPL-SR

```

04: 118-158 CPEEKQRHLDDKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL-OH

The fragments are depicted as their thioesters (-SR) wherein X represents a temporary protecting group that is removed after the particular fragment has been coupled (e.g. the MSC-group). The synthesis process is: coupling fragment 04 to fragment 03, followed by removal X from construct 03/04, coupling fragment 03/04 to fragment 02, removal X from construct 02/03/04, coupling fragment 02/03/04 to fragment 01.

10 Example 3: Chemical synthesis of HPV16 E2

HPV16-E2 PROTEIN SEQUENCE

15
001 METLCQRLNV CQDKILTHYE NDSTDLRDHI DYWKHMRLEC AIYYKAREMG FKHINHQVVP
061 TLAVSKNKAL QAIELQLTLE TIYNSQYSNE KWTLDQVSLE VYLTAPTGCI KKHGYTVEVQ
121 FDGDI~~C~~NTMH YTNWTHIYIC EEASVTVEG QVDYYGLYYV HEGIRTYFVQ FKDDAEKYSK
181 NKVWEVHAGG QVILCPTSVF SSNEVSSPEI IRQHLANHPA ATHTKAVALG TEETQTTIOR
20 241 PRSEPDTGNP CHTTKLLHRD SVDSAPILTA FNSSHKGRIN CNSNTTPIVH LKGDANTLKC
301 LRYRFKKHCT LYTAVSSTWH WTGHNVKHKSAIVTLTYDSE WQRDQFLSQV KIPKTITVST
361 GFMSI

Seven fragments selected for peptide synthesis to obtain full length HPV16 E2 synthetic protein:

25 01:001-039 METLCQRLNVCQDKILTHYENDSTDLRDHIDYWKHMRLE-SR
02:040-108 X-CAIYYKAREMGFKKHINHQVVP TLAVSKNKALQAIELQLTLE TIYNSQYSNE
KWTLDQVSLE VYLTAPTG-SR
30 03:109-139 X-CIKKHGYTVEVQFDGDI~~C~~NTMHYTNWTHIYI-SR
04:140-194 X-CEEASVTVEGQVDYYGLYYVHEGIRTYFVQFKDDAEKYSKNK
VWEVHAGGQVIL-SR
35 05:195-250 X-CPTSVFSSNEVSSPEIIRQHLANHPAATHTKAVALGTEETQTTIOR
PRSEPDTGNP-SR
40 06:251-299 X-CHTTKLLHRDSVDSAPILTA FNSSHKGRINCNSNTTPIVHLKGD
ANTLK-SR
07:300-365 CLRYRFKKHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQFLSQV
KIPKTITVSTGFMSI

The fragments are depicted as their thioesters (-SR), wherein X represents a temporary protecting group that is removed after the particular fragment has been coupled (e.g. the MSC-group). The synthesis strategy is comparable with HPV16 E6.

Note: coupling between construct 06/07 and fragment 05 can be difficult because this
5 coupling is to a P.

HPV16-E2, alternative strategy, two overlapping parts of the protein, glycine-ligation.

10 Normally chemical ligation proceeds by coupling of an C-terminal thioester of a fragment to an N-terminal C of another fragment, due to lenght restrictions and/or an unfavourable sequence. In case of HPV16E2 an alternative strategy can be used:

15 PART 1: 001-210

01:001-039 METLCQRLNV CQDKILTHYE NDSTDLRDHI DYWKHMRLE-SR

02:040-108 X-CAIYYKAREMGFKHINHQVPTLAVSKNKALQAIELQLTLE
TIYNSQYSNEKWTLDVSLLEVYLTAPTG-SR

20 03:109-155 X-CIKKHGYTVEVQFDGDCNTMHYTNWTHIYICEEASVTVEG
QVDYY-SR

25 04:156-210 XX-GLYYVHEGIRTYFVQFKDDAEKYSKNKVWEVHAGGQVILCPTSVF
SSNEVSSPEI

PART 2: 190-365

30 01:190-229 GQVILCPTSVFSSNEVSSPEIIRQHLANHPAATHTKAVAL-SR

02:230-280 XX-GTEETQTTIQRPRSEPDTGNPCHTTKLLHRDSVDSAPILTA
FNSSHKGRIN-SR

35 03:281-308 X-CNSNTPIVHLKGDANTLKCLRYRFKKH-SR

40 04:309-365 CTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWORDQFLSQV
KIPKTITVSTGFMSI

Fragments are depicted as their thioesters (-SR) wherein X represents a temporary protecting group that is removed after the particular fragment has been coupled (e.g. the MSC-group), XX-represents an S-protected N-(2,3,4-trimethoxy-5-mercaptophenyl)group attached to the N-terminal G [J. Am. Chem. Soc. 124, 4642 (2002)].

Example 4: Chemical synthesis of HPV18 E7

HPV18-E7 PROTEIN SEQUENCE

```
01 MHGPKATLQD IVLHLEPONE IPVDLLCHEQ LSDSEEENDE IDGVNHQHLF ARRAEPQRHT
61 MLCMCCKCEA RIELVVESSA DDLRAFQQLF LNTLSFVCPW CASQQ
```

Two fragments selected for peptide synthesis to obtain full length HPV18 E2 synthetic protein, details identical to example 1:

```
01:001-065      MHGPKATLQDIVLHLEPONEIPVDLLCHEQLSDSEEENDEIDGVNHQHLF
ARRAEPQRHT MLCMC-SR
02:066-099      CKCEA RIELVVESSA DDLRAFQQLF LNTLSFVCPW CASQQ
```

Example 5: Chemical synthesis of HPV18 E6

HPV18-E6 PROTEIN SEQUENCE

```
001 MARFEDPTRR PYKLPDLCTE LNTSLQDIEI TCVYCKTVLE LTFVFEFAFK DLFVVYRDSI
061 PHAACHKCID FYSRIREL RH YSDSVYGD TL EKL TNTGLYN LLIRCLRCQK PLNPAEKL RH
121 LNEKRRFHNI AGHYRGQCHS CCNRRARQERL QRRRETQV
```

Four fragments selected for peptide synthesis to obtain full length HPV18 E6 synthetic protein:

```
01:001-034      MARFEDPTRR PYKLPDLCTE LNTSLQDIEITCVY-SR
02:035-064      X-CKTVLE LTFVFEFAFK DLFVVYRDSI PHAA-SR
03:065-104      X-CHKCID FYSRIREL RH YSDSVYGD TL EKL TNTGLYN LLIR-SR
04:105-158      CLRCQK PLNPAEKL RH LNEKRRFHNI AGHYRGQCHS CCNRRARQERL
QRRRETQV
```

Fragments are depicted as their thioesters (-SR), wherein X represents a temporary protecting group that is removed after the particular fragment has been coupled (e.g. the MSC-group).

5

Example 6: Chemical synthesis of HPV18 E2

HPV18-E2 PROTEIN SEQUENCE

10

001 MQTPKETLSE RLSCVQDKII DHYENDSKDI DSQIQYWQLI RWENAIFFAA REHGIQTLNH
 061 QVVPAYNISK SKAHKAIELQ MALQGLAQSR YKTEDWTLQD TCEELWNTEP THCFKKGGQT
 121 VQVYFDGNKD NCMTYVAWDS VYYMTDAGTW DKTATCVSHR GLYYVKEGYN TFYIEFKSEC
 15 181 EKYGNTGTWE VHFGNNVIDC NDSMCSTSD TVSATQLVKQ LQHTPSPYSS TVSVGTAKTY
 241 GQTSAAATPG HCGLAEKQHC GPVNPLLGA TPTGNNKRRK LCGNTTPII HLKGDRLNSLK
 301 CLRYRLRKHS DHYRDISSTW HWTGAGNEKT GILTVTYHSE TQRTKFLNTV AIPDSVQILV
 361 GYMTM

20 Seven fragments selected for peptide synthesis to obtain full length HPV18 E2 synthetic protein:

25	01:001-013	MQTPKETLSERLS-SR
	02:014-101	X-CVQDKIIDHYENDSKDIDSQIQYWQLIRWENAIFFAAREHGIQTLNH QVVPAYNISKSKAHKAIELQMALQGLAQSR YKTEDWTLQDT-SR
30	03:102-155	X-CEELWNTEPTHCFKKGGQTVQVYFDGNKDCMTYVAWDS VYYMTDAGTW DKTAT-SR
	04:156-199	X-CVSHRGLYYVKEGYNTFYIEFKSECEKYGNTGTWEVHFGNNVID-SR
35	05:200-251	X-CNDSMCSTSDT TVSATQLVKQLQHTPSPYSSTVSVGTAKTY GQTSAAATPGH-SR
	06:252-300	X-CGLAEKQHCGPVNPLLGAATPTGNNKRRKLCGNTTPIIHLKGD RNSLK-SR
40	07:301-365	X-CLRYRLRKHSDHYRDISSTWHWTGAGNEKTGILTVTYHSE TQRTKFLNTVAIPDSVQILVGYMTM

45 Fragments are depicted as their thioesters (-SR) wherein X represents a temporary protecting group that is removed after the particular fragment has been coupled (e.g. the MSC-group).

HPV18-E2, alternative strategy, two overlapping parts of the protein, glycine-ligation.

Preferably chemical ligation proceeds by coupling of an C-terminal thioester of a fragment to an N-terminal C of another fragment, due to length restrictions and/or an unfavourable sequence. In case of HPV16E2 an alternative strategy can be used:

5

PART 1: 001-210

10

01:001-053 MQTPKETLSERLSCVQDKIIDHYENDSKDIDSQIQYWQLI
RWENAIFFAAREH-SR

02:054-112 XX-GIQTILNHQVVPAYNISKSKAHKAIELQMALQGLAQSRKTEDWTLOD
TCEELWNTEPTH-SR

15

03:113-155 X-CFKKGG VQVYFDGNKD NCMTYVAWDS VYYMTDAGTW DKTAT-SR

04:156-210 X-CVSHRGLYYVKEGYN TFYIEFKSEC EKYGNTGTWE VHFGNNVIDC
NDSMCSTSD

20

PART 2: 191-365

25

01:191-251 VHFGNNVIDCNDSMCSTSDDTVSATQLVKQLQHTPSPYSS
TVSVGTAKTYGQTSAAATRPGH-SR

02:252-300 X-CGLAEKQHCGPVNPLLGAATPTGNNKRRKLCSGNTTPIIHLKGD
RNSLK-SR

30

03:301-365 X-CLRYRLRKHSDDHYRDISSTWHWTGAGNEKTGILTVTYHSE
TQRTKFLNTVAIPDSVQILVGYMTM

35 Fragments are depicted as their thioesters (-SR) wherein X represents a temporary protecting group that is removed after the particular fragment has been coupled (e.g. the MSC-group) and XX-represents an S-protected N-(2,3,4-trimethoxy-5-mercaptophenyl)group attached to the N-terminal G [J. Am. Chem. Soc. 124, 4642 (2002)].

Example 7: Antigenicity of synthetic HPV16-E7 protein vaccine

40 Methods:

Control antigens and adjuvants. Two peptides were generated, the H-2D^b-restricted CTL epitope HPV16-E7₄₉₋₅₇ (RAHYNIVTF) and the E7₄₃₋₇₇ 35 residue long peptide GQAEPDRAHYNIVTFCCKCDSTLRLCVQSTHVDIR. The purity of the peptides was determined by RP-HPLC and was found to be routinely over 90% pure.

Peptides were dissolved in 0.5% DMSO in PBS and, if not used immediately, stored at -20°C. The recombinant was produced in recombinant *E. coli* transformed with Pet-19b-HPV16-E7 and purified as described previously (De Bruijn, M.L. et al., Cancer Res. 58 p 724-31, 1999). CpG-oligodeoxynucleotides (ODN) 1826, sequence
5 TTCATGACGTTCTGACGTT, were provided by Coley Pharmaceutical and used at a working concentration of 50 µg/mouse (Zwaveling S. et al., J. Immunol. 169, p350-8, 2002).

Mice, immunizations, cell lines and T-cell cultures. C57BL/6 (B6, H-2^b) mice were obtained from IFFA Credo (Paris, France). Tumor cell line 13.2 was derived from
10 MEC (B6) transformed with adenovirus type 5-derived E1 protein in which the H-2D^b E1A epitope was replaced with the HPV16-E7₄₉₋₅₇ CTL epitope. TC-1, which was derived from primary epithelial cells of C57BL/6 mice cotransformed with HPV-16 E6 and E7 and c-Ha-ras oncogenes were cultured in IMDM + 10% FCS (Van der Burg S. H. et al., Vaccine 19, 3652-60, 2001). D1 cells are long-term growth factor dependent
15 immature splenic dendritic cells (DC) derived from C57BL/6 mice and were cultured as described (Winzler C. et al., J. Exp. Med. 185, p317-28, 1997). C57BL/6 mice were injected subcutaneously with equimolar levels (4.5 nmol) of either the E7₄₉₋₅₇ short peptide (5.0 µg), or E7₄₃₋₇₇ 35-residue long peptide (18 µg), recombinant HPV16-E7 (50 µg) or synthetic HPV16-E7 protein (50 µg) dissolved in PBS. ODN-CpG 1826 (50
20 µg) was dissolved in PBS and mixed with the peptides before subcutaneous vaccination. As a positive control, mice were also injected with an approximately 8-fold higher dose of peptide (37.7 nmol, 150µg) dissolved in PBS and mixed with ODN-CpG 1826 (Zwaveling et al., J. Immunol. 169, p 350-8, 2002). The total injected volume was 200 µl/mouse. Spleens were harvested after 10 days. T cells were obtained
25 from immunized mice by culturing spleen cells (4x10⁶ cells/well of a 24-wells plate) in complete medium in the presence of 5x10⁵ E7₄₉₋₅₇-expressing cells (tumor cell line 13.2). Cultures were maintained at 37°C in humidified air containing 5% CO₂. No exogenous IL-2 was added. On day six, dead cells were removed from the culture by centrifugation over a Ficoll density gradient and remaining viable cells were seeded in
30 24-wells plates at 1.5x10⁶ cells/well. On day seven, tetramer staining or intracellular cytokine staining was performed.

Analysis of HPV16-E7-specific CD8⁺ T-cells. PE-labeled H-2D^b epitope E7₄₉₋₅₇ (RAHYNIVTF)-containing tetramers were constructed and used for the analysis of

peptide-specific CTL-immunity as described earlier (Van der Burg et al., Vaccine 19, p 3652-60, 2001). FITC-labeled anti-CD8b.2 Ab (Ly-3.2) (clone 53-5.8) and PE-labeled anti-IFN γ Ab (clone XMG1.2) (BD Pharmingen, San Diego, USA) were used for the analysis of antigen-specific IFN γ production of HPV16-E7-specific CTL as described previously (Zwaveling S. et al., J. Immunol. 169 p 350-8, 2002).

Tumour challenge experiments. In prophylactic vaccination strategy experiments the mice were subcutaneously vaccinated at day -28 and day -14 with indicated vaccines at their left flank. At day 0, mice were subcutaneously injected with 50.000 TC-1 tumour cells and tumour growth was followed for 100 days. In the therapeutic vaccination setting mice were challenged at the left flank with 50.000 TC-1 tumourcells. At day 9, when tumours were palpable, mice were vaccinated at the right flank with indicated vaccines. Fourteen days later these mice received a booster injection with the vaccinevaccination. Tumour growth was monitored for 95 days.

15 In vivo antigenicity of synthetic HPV16-E7 protein

Since numerous studies show that: (1) protection of C57BL/6 mice against HPV16-E7-expressing tumors is largely dependent on E7₄₉₋₅₇-specific CD8⁺ T cells (De Bruijn M.L. et al., Cancer Res. 58, p 724-31, 1998, Greenstone H.L. et al., PNAS 95, p 1800-5, 1998, Lin K.Y. et al., Cancer Res. 56, p21-6, 1996, Feltkamp M. C. et al., Eur. J. Immunol. 23, p 2242-9,, 1993), and (2) that the ability of HPV16-E7-specific T-cells to protect against tumor development or to eradicate established tumors is correlated with the percentage of E7₄₉₋₅₇-tetramer positive CD8⁺ T-cells (Van der Burg et al., Vaccine 19, p 3652-60, 2001), the antigenicity of synthetic HPV16-E7 protein was assessed by its capacity to induce such HPV16-E7₄₉₋₅₇-specific CD8⁺ T-cells. C57BL/6 mice were injected with several vaccines that have been used successfully in the past, including the minimal CTL epitope (E7₄₉₋₅₇: RAHYNIVTF), a longer peptide (E7₄₃₋₇₇) that was known to induce vigorous E7₄₉₋₅₇-specific CD8⁺ T-cell responses, recombinant HPV16-E7 or the synthetic HPV16-E7 protein at equimolar concentrations of the minimal CTL epitope, in combination with CpG. Ten days following vaccination, the spleens were harvested and the cells directly analysed by H2-D^b E7₄₉₋₅₇ (RAHYNIVTF)-tetramer staining (Van der Burg S.H. Vaccine 19, p 3652-60, 2001) (Figure 3a) as well as subjected to an extra round of in vitro stimulation, which magnifies but does not alter the hierarchy of in vivo induced CD8⁺ T cell responses,

before the percentage of E7₄₉₋₅₇ peptide-specific CD8⁺ T-cells was determined (Figure 3b). As expected, the longer E7 peptide was able to induce strong HPV16-E7-specific CD8⁺ T-cells at a high antigen dose as well as at the lower dose, whereas the response induced by the minimal CTL epitope was significantly lower. Importantly, the HPV16-E7-specific CD8⁺ T-cell response induced by one single injection of synthetic E7 protein was comparable to that of the recombinant HPV16-E7 protein and somewhat higher than the other vaccines. To confirm that functional CD8⁺ T-cell responses were triggered following a single vaccination with the synthetic E7 protein, the numbers of INF- γ -producing CD8⁺ cells were measured upon stimulation with dendritic cells (DC) only, or pulsed with either the long E7₄₃₋₇₇ peptide or the recombinant E7 protein. High numbers of INF γ -producing CD8⁺ T-cells were detected in the spleens of mice vaccinated with the synthetic E7 protein, confirming that the CD8⁺ T-cells detected by the H2-D^b E7₄₉₋₅₇-tetramers were functionally active (Figure 4). Furthermore, the CD8⁺ T-cells from these mice reacted against recombinant E7 protein-pulsed DC, indicating that the synthetic HPV16-E7 protein retained its full antigenic potential.

The synthetic E7-protein vaccination results in eradication of TC-1 tumour cells.

Following a challenge with 50,000 TC-1 tumour cells, naïve mice started to develop palpable tumours from day 11 onwards and all mice died within 41 days after tumour inoculation. Mice vaccinated with 4.5 nmol of the synthetic E7 protein in a prime-boost protocol were protected till day 70. After this day only one of the ten mice vaccinated with synthetic E7 developed a tumour while from the group of mice that were vaccinated with recombinant E7 protein 3 mice died. When mice were vaccinated with an equimolar amount of long E7 peptide all mice developed a tumour (Figure 5a) but of the mice injected with the previously established protective, approximately 8-fold, higher dose of long peptide (13) only 4 developed a tumour. In order to test the capacity of this vaccine to eradicate an established tumour, mice were first challenged with TC-1 tumour cells and vaccinated at day 9 when tumours were palpable. A booster vaccination was given 14 days later. Naïve mice all died within 39 days after tumour challenge. Of the mice injected with a low dose of long peptide (equimolar amount to synthetic protein) >40% were still alive at day 40 but eventually all mice died before day 56. Of the 8 mice that were vaccinated with synthetic E7 protein six mice died between day 50 and 70, while the last 2 mice survived at least until to day 95. Mice

vaccinated with recombinant E7 protein died somewhat quicker but the survival kinetics were similar to that of the group vaccinated with the synthetic protein (Figure 5b).

The experiments above demonstrate that the synthetic E7 protein induces strong CD8+ IFN γ -producing T-cell immunity that is capable of protecting mice against tumours in both prophylactic and therapeutic settings. Therapeutic vaccination with synthetic E7 did not result in the eradication of tumours in all mice but this may be related to the aggressiveness of TC-1 tumour growth observed in these experiments. Palpable tumours not only appeared significantly earlier after injection of TC-1 cells but also their growth rate was higher since all mice died within 7 -days (Figure 5b) while in our previous experiments naïve mice died within 14-21 days (Van der Burg S.H. Vaccine 19, p3652-60, 2001). Even the high-dose of long peptide, which in our previous study protected mice extremely well (Zwaveling S. et al., J. Immunol. 169, p350-8, 2002), was not capable of completely preventing the development of tumours in our current study.

Compared with the recombinant or the synthetic E7 protein, vaccination with an equimolar dose of long E7 peptide was not efficient in the induction of CD8+ IFN γ -producing HPV16 E7-specific T-cells and this was reflected in the lack of protection against a tumour challenge. Since vaccination with a ~8 fold higher dose of long peptide did result in a strong E7-specific T-cell response and tumour protection and that the longevity of antigen presentation at the site of CpG mediated DC activation plays an important role. This is related to the in vitro/vivo susceptibility of peptides and proteins to proteolytic breakdown and with differences in the spreading of proteins and peptides, but also of the adjuvant CpG, throughout the body. Our data show that at an equimolar basis, synthetic proteins have a more favourable profile for vaccination purposes.

Claims

1. A method for producing a synthetic protein comprising an amino acid sequence that is at least 80% identical to at least 46 contiguous amino acids of a naturally occurring antigenic protein of a pathogen or tumor, wherein the method comprises the steps of:
 - a) chemically synthesizing two or more fragments each consisting of 2 – 80 contiguous amino acids of the amino acid sequence, whereby in the amino acid sequence the two or more fragments are neighbouring and non-overlapping;
 - b) chemically ligating the C-terminus of a fragment to the N-terminus of a neighbouring fragment to produce the synthetic protein or a part thereof;
 - c) optionally, repeating step B to sequentially ligate a further neighbouring fragment obtained from step B or step C to produce the synthetic protein.
2. A method according to claim 1, wherein the neighbouring non-overlapping fragments are selected to comprise a N-terminal cysteine or glycine residue.
3. A method according to claims 1 or 2, wherein the naturally occurring protein is an HPV protein.
4. A method according to any one of claims 1-3, wherein the HPV protein is an E2, E6 or E7 protein from HPV16, HPV18, HPV31, HPV33 or HPV45.
5. A method according to any one of claims 1-4, wherein the synthetic protein obtained from step B or C is chemically conjugated to an adjuvant.
6. A method according to claim 5, wherein the adjuvant is chemically synthesized.
7. A method according to claims 5 or 6, wherein the adjuvant is capable of activating dendritic cells.
8. A method according to claim 7, wherein the adjuvant is selected from the group consisting of polyIC, CpG DNA, imiquimod, Pam3Cys, LPS and combinations

thereof.

9. A method according to any one of claims 1-8, further comprising the step of
formulating the synthetic protein into a pharmaceutical composition by mixing the
5 protein with a pharmaceutically acceptable carrier.
10. A composition comprising a synthetic protein, the protein comprising an amino
acid sequence that is at least 80% identical to at least 46 contiguous amino acids of
of a naturally occurring antigenic protein of a pathogen or tumor, whereby the
10 composition is free of a nucleic acid encoding the amino acid sequence.
11. A composition according to claim 10, wherein the protein comprises an amino acid
sequence that is at least 80% identical to at least 46 contiguous amino acids of one
of SEQ ID's No. 1 to 6, whereby the composition is free of DNA encoding the
15 amino acid sequences of SEQ ID NO 1-6.
12. A composition according to claim 11, whereby composition further comprises an
adjuvant.
- 20 13. A composition according to claim 12, wherein the adjuvant is capable of activating
dendritic cells.
14. A composition according to claim 13, wherein the adjuvant TLR-activating
adjuvant is selected from a group consisting of polyIC, CpG DNA, imiquimod,
25 Pam3Cys, LPS and combinations thereof.
15. A composition according to any one of claims 10-14, whereby the adjuvant is
covalently conjugated to the protein.
- 30 16. A composition according to any one of claims 9-15, whereby the composition
further comprises a pharmaceutically acceptable carrier.

17. A composition according to any one of claims 9-16, whereby the composition further comprises anti-CD40 antibody.

18. A composition according to any one of claims 9-17 for use as a vaccine.

5

19. A method for the treatment or prevention of an HPV associated disease, the method comprising the administration to a subject of a synthetic protein produced as defined in claims 1-9, or a composition as defined in claims 10-18, in a therapeutically effective amount.

10

20. A method according to claim 19, wherein the HPV associated disease is an HPV-induced cancer.

21. Use of a synthetic protein produced as defined in claims 1-9, or a composition as defined in claims 10-18, for the manufacture of a medicament for the treatment or prevention of an HPV associated disease.

15

22. A use according to claim 21, wherein the HPV associated disease is an HPV-induced cancer.

20







Fig 2**Fig 3a****Fig 3b**

3/4






Fig 4

4/4

Fig 5a*Fig 5b*

SEQUENCE LISTING

5 <110> Leiden University Medical Center

10 <120> Synthetic protein as tumor-specific vaccine

15 <130> P210601 pct

20 <160> 6

<170> PatentIn version 3.1

25

<210> 1

<211> 98

30

<212> PRT

<213> Human papillomavirus type 16

35

<400> 1

40 Met His Gly Asp Thr Pro Thr Leu His Glu Tyr Met Leu Asp Leu Gln
1 5 10 15

Pro Glu Thr Thr Asp Leu Tyr Cys Tyr Glu Gln Leu Asn Asp Ser Ser
20 25 30

45

Glu Glu Glu Asp Glu Ile Asp Gly Pro Ala Gly Gln Ala Glu Pro Asp
35 40 45

50

Arg Ala His Tyr Asn Ile Val Thr Phe Cys Cys Lys Cys Asp Ser Thr
50 55 60

55

Leu Arg Leu Cys Val Gln Ser Thr His Val Asp Ile Arg Thr Leu Glu
65 70 75 80

60

Asp Leu Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln
85 90 95

Lys Pro

5

<210> 2

<211> 158

10

<212> PRT

<213> Human papillomavirus type 16

15

<400> 2

Met His Gln Lys Arg Thr Ala Met Phe Gln Asp Pro Gln Glu Arg Pro
1 5 10 15

20

Arg Lys Leu Pro Gln Leu Cys Thr Glu Leu Gln Thr Thr Ile His Asp
20 25 30

25

Ile Ile Leu Glu Cys Val Tyr Cys Lys Gln Gln Leu Leu Arg Arg Glu
35 40 45

30

Val Tyr Asp Phe Ala Phe Arg Asp Leu Cys Ile Val Tyr Arg Asp Gly
50 55 60

35

Asn Pro Tyr Ala Val Cys Asp Lys Cys Leu Lys Phe Tyr Ser Lys Ile
65 70 75 80

40

Ser Glu Tyr Arg His Tyr Cys Tyr Ser Leu Tyr Gly Thr Thr Leu Glu
85 90 95

45

Gln Gln Tyr Asn Lys Pro Leu Cys Asp Leu Leu Ile Arg Cys Ile Asn
100 105 110

50

Cys Gln Lys Pro Leu Cys Pro Glu Glu Lys Gln Arg His Leu Asp Lys
115 120 125

55

Ser Cys Cys Arg Ser Ser Arg Thr Arg Arg Glu Thr Gln Leu
145 150 155

<210> 3

60

<211> 365

<212> PRT

<213> Human papillomavirus type 16

5

<400> 3

10 Met Glu Thr Leu Cys Gln Arg Leu Asn Val Cys Gln Asp Lys Ile Leu
 1 5 10 15
 15 Thr His Tyr Glu Asn Asp Ser Thr Asp Leu Arg Asp His Ile Asp Tyr
 20 25 30
 Trp Lys His Met Arg Leu Glu Cys Ala Ile Tyr Tyr Lys Ala Arg Glu
 35 40 45
 20 Met Gly Phe Lys His Ile Asn His Gln Val Val Pro Thr Leu Ala Val
 50 55 60
 25 Ser Lys Asn Lys Ala Leu Gln Ala Ile Glu Leu Gln Leu Thr Leu Glu
 65 70 75 80
 30 Thr Ile Tyr Asn Ser Gln Tyr Ser Asn Glu Lys Trp Thr Leu Gln Asp
 85 90 95
 35 Val Ser Leu Glu Val Tyr Leu Thr Ala Pro Thr Gly Cys Ile Lys Lys
 100 105 110
 His Gly Tyr Thr Val Glu Val Gln Phe Asp Gly Asp Ile Cys Asn Thr
 115 120 125
 40 Met His Tyr Thr Asn Trp Thr His Ile Tyr Ile Cys Glu Glu Ala Ser
 130 135 140
 45 Val Thr Val Val Glu Gly Gln Val Asp Tyr Tyr Gly Leu Tyr Tyr Val
 145 150 155 160
 50 His Glu Gly Ile Arg Thr Tyr Phe Val Gln Phe Lys Asp Asp Ala Glu
 165 170 175
 55 Lys Tyr Ser Lys Asn Lys Val Trp Glu Val His Ala Gly Gly Gln Val
 180 185 190
 Ile Leu Cys Pro Thr Ser Val Phe Ser Ser Asn Glu Val Ser Ser Pro
 195 200 205
 60 Glu Ile Ile Arg Gln His Leu Ala Asn His Pro Ala Ala Thr His Thr

	210	215	220	
5	Lys 225	Ala Val Ala Leu Gly 230	Thr Glu Glu Thr Gln 235	Thr Thr Ile Gln Arg 240
10	Pro Arg Ser Glu 245	Pro Asp Thr Gly Asn 250	Pro Cys His Thr Thr 255	Lys Leu 255
15	Leu His Arg Asp 260	Ser Val Asp Ser Ala 265	Pro Ile Leu Thr Ala 270	Phe Asn 270
20	Ser Ser His Lys 275	Gly Arg Ile Asn Cys 280	Asn Ser Asn Thr Thr 285	Pro Ile 285
25	Val His Leu Lys 290	Gly Asp Ala Asn Thr 295	Leu Lys Cys Leu Arg 300	Tyr Arg 300
30	Phe Lys Lys His 305	Cys Thr Leu Tyr Thr 310	Ala Val Ser Ser Thr 315	Trp His 320
35	Trp Thr Gly His 325	Asn Val Lys His Lys 330	Ser Ala Ile Val Thr 335	Leu Thr 335
40	Tyr Asp Ser Glu 340	Trp Gln Arg Asp Gln 345	Phe Leu Ser Gln Val 350	Lys Ile 350
45	Pro Lys Thr 355	Ile Thr Val Ser Thr 360	Gly Phe Met Ser Ile 365	
50	<210> 4			
	<211> 105			
	<212> PRT			
	<213> Human papillomavirus type 18			
55	<400> 4			
60	Met His Gly Pro Lys Ala Thr Leu Gln Asp Ile Val Leu His Leu Glu 1 5 10 15			
	Pro Gln Asn Glu Ile Pro Val Asp Leu Leu Cys His Glu Gln Leu Ser 20 25 30			
	Asp Ser Glu Glu Glu Asn Asp Glu Ile Asp Gly Val Asn His Gln His 35 40 45			

5 Leu Pro Ala Arg Arg Ala Glu Pro Gln Arg His Thr Met Leu Cys Met
 50 55 60

10 Cys Cys Lys Cys Glu Ala Arg Ile Glu Leu Val Val Glu Ser Ser Ala
 65 70 75 80

15 Asp Asp Leu Arg Ala Phe Gln Gln Leu Phe Leu Asn Thr Leu Ser Phe
 85 90 95

20 Val Cys Pro Trp Cys Ala Ser Gln Gln
 100 105

25 <210> 5
 <211> 158
 <212> PRT
 <213> Human papillomavirus type 18

30 Met Ala Arg Phe Glu Asp Pro Thr Arg Arg Pro Tyr Lys Leu Pro Asp
 1 5 10 15

35 Leu Cys Thr Glu Leu Asn Thr Ser Leu Gln Asp Ile Glu Ile Thr Cys
 20 25 30

40 Val Tyr Cys Lys Thr Val Leu Glu Leu Thr Glu Val Phe Glu Phe Ala
 35 40 45

45 Phe Lys Asp Leu Phe Val Val Tyr Arg Asp Ser Ile Pro His Ala Ala
 50 55 60

50 Cys His Lys Cys Ile Asp Phe Tyr Ser Arg Ile Arg Glu Leu Arg His
 65 70 75 80

55 Tyr Ser Asp Ser Val Tyr Gly Asp Thr Leu Glu Lys Leu Thr Asn Thr
 85 90 95

60 Gly Leu Tyr Asn Leu Leu Ile Arg Cys Leu Arg Cys Gln Lys Pro Leu
 100 105 110

Asn Pro Ala Glu Lys Leu Arg His Leu Asn Glu Lys Arg Arg Phe His
 115 120 125

Asn Ile Ala Gly His Tyr Arg Gly Gln Cys His Ser Cys Cys Asn Arg
 130 135 140

5

Ala Arg Gln Glu Arg Leu Gln Arg Arg Arg Glu Thr Gln Val
 145 150 155

10 <210> 6

<211> 365

<212> PRT

15 <213> Human papillomavirus type 18

20 <400> 6

Met Gln Thr Pro Lys Glu Thr Leu Ser Glu Arg Leu Ser Cys Val Gln
 1 5 10 15

25

Asp Lys Ile Ile Asp His Tyr Glu Asn Asp Ser Lys Asp Ile Asp Ser
 20 25 30

30

Gln Ile Gln Tyr Trp Gln Leu Ile Arg Trp Glu Asn Ala Ile Phe Phe
 35 40 45

35

Ala Ala Arg Glu His Gly Ile Gln Thr Leu Asn His Gln Val Val Pro
 50 55 60

40

Ala Tyr Asn Ile Ser Lys Ser Lys Ala His Lys Ala Ile Glu Leu Gln
 65 70 75 80

45

Met Ala Leu Gln Gly Leu Ala Gln Ser Arg Tyr Lys Thr Glu Asp Trp
 85 90 95

50

Thr Leu Gln Asp Thr Cys Glu Glu Leu Trp Asn Thr Glu Pro Thr His
 100 105 110

55

Cys Phe Lys Lys Gly Gly Gln Thr Val Gln Val Tyr Phe Asp Gly Asn
 115 120 125

60

Lys Asp Asn Cys Met Thr Tyr Val Ala Trp Asp Ser Val Tyr Tyr Met
 130 135 140

Thr Asp Ala Gly Thr Trp Asp Lys Thr Ala Thr Cys Val Ser His Arg
 145 150 155 160

	Gly	Leu	Tyr	Tyr	Val	Lys	Glu	Gly	Tyr	Asn	Thr	Phe	Tyr	Ile	Glu	Phe	
					165					170					175		
5	Lys	Ser	Glu	Cys	Glu	Lys	Tyr	Gly	Asn	Thr	Gly	Thr	Trp	Glu	Val	His	
				180					185					190			
10	Phe	Gly	Asn	Asn	Val	Ile	Asp	Cys	Asn	Asp	Ser	Met	Cys	Ser	Thr	Ser	
			195					200					205				
15	Asp	Asp	Thr	Val	Ser	Ala	Thr	Gln	Leu	Val	Lys	Gln	Leu	Gln	His	Thr	
		210					215					220					
20	Pro	Ser	Pro	Tyr	Ser	Ser	Thr	Val	Ser	Val	Gly	Thr	Ala	Lys	Thr	Tyr	
	225					230					235					240	
25	Gly	Gln	Thr	Ser	Ala	Ala	Thr	Arg	Pro	Gly	His	Cys	Gly	Leu	Ala	Glu	
					245					250					255		
30	Lys	Gln	His	Cys	Gly	Pro	Val	Asn	Pro	Leu	Leu	Gly	Ala	Ala	Thr	Pro	
				260					265					270			
35	Thr	Gly	Asn	Asn	Lys	Arg	Arg	Lys	Leu	Cys	Ser	Gly	Asn	Thr	Thr	Pro	
			275					280					285				
40	Ile	Ile	His	Leu	Lys	Gly	Asp	Arg	Asn	Ser	Leu	Lys	Cys	Leu	Arg	Tyr	
		290					295					300					
45	Arg	Leu	Arg	Lys	His	Ser	Asp	His	Tyr	Arg	Asp	Ile	Ser	Ser	Thr	Trp	
	305					310					315					320	
50	His	Trp	Thr	Gly	Ala	Gly	Asn	Glu	Lys	Thr	Gly	Ile	Leu	Thr	Val	Thr	
					325					330					335		
55	Tyr	His	Ser	Glu	Thr	Gln	Arg	Thr	Lys	Phe	Leu	Asn	Thr	Val	Ala	Ile	
				340					345					350			
60	Pro	Asp	Ser	Val	Gln	Ile	Leu	Val	Gly	Tyr	Met	Thr	Met				
			355					360					365				

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NL 03/00929

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K39/00 C07K14/00 C07K14/025

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/12281 A (HUNG CHIEN FU ; WU TZYY CHOOU (US); UNIV JOHNS HOPKINS (US)) 14 February 2002 (2002-02-14)	10,11, 16,18-22
Y	page 28; sequence 5	1-7, 9-13, 15-22
X	WO 00/75336 A (GUILLET JEAN GERARD ; INST NAT. SANTE RECH MED (FR); CONNAN FRANCINE (F) 14 December 2000 (2000-12-14)	10,11, 16,18-22
Y	sequence 12	1-7, 9-13, 15-22
	----- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

28 July 2004

Date of mailing of the international search report

03. 01. 05

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Wimmer, G

INTERNATIONAL SEARCH REPORT

International Application No
PCT/NL 03/00929

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	TAM J P ET AL: "Tandem peptide ligation for synthetic and natural biologicals" September 2001 (2001-09), BIOLOGICALS, VOL. 29, NR. 3-4, PAGE(S) 189-196 , XP002290180 ISSN: 1045-1056 the whole document	1-7, 9-13, 15-22
X	KELL BARBARA ET AL: "Detection of E5 oncoprotein in human papillomavirus type 16-positive cervical scrapes using antibodies raised to synthetic peptides" JOURNAL OF GENERAL VIROLOGY, vol. 75, no. 9, 1994, pages 2451-2456, XP009034550 ISSN: 0022-1317 the whole document	10
A	NARDIN E H ET AL: "A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 JAN 2001, vol. 166, no. 1, 1 January 2001 (2001-01-01), pages 481-489, XP002290179 ISSN: 0022-1767 the whole document	8,14
A	WO 90/13564 A (CONNAUGHT LAB) 15 November 1990 (1990-11-15) the whole document	1-22

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NL 03/00929

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-22 (partially)

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: Claims 1-22 (partially)

A method of producing a synthetic protein comprising an amino acid sequence that is at least 80% identical to at least 46 contiguous amino acids of a naturally occurring antigenic protein of a pathogen or tumor, comprising the steps of synthesizing two or more fragments and ligating the fragments,
wherein the synthetic protein is at least 80% identical to 46 contiguous amino acids of SEQ ID NO.1

Inventions 2-6: Claims 1-22 (partially)

As Invention 1, with SEQ ID NOs. 2-6, respectively.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NL 03/00929

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0212281	A	14-02-2002	AU 7811701 A CA 2417214 A1 EP 1363938 A2 JP 2004527213 T WO 0212281 A2	18-02-2002 14-02-2002 26-11-2003 09-09-2004 14-02-2002
WO 0075336	A	14-12-2000	FR 2794370 A1 AU 5229400 A AU 5411000 A CA 2375602 A1 CA 2375627 A1 EP 1181314 A1 EP 1183368 A2 WO 0075336 A2 WO 0075181 A1 US 6783763 B1	08-12-2000 28-12-2000 28-12-2000 14-12-2000 14-12-2000 27-02-2002 06-03-2002 14-12-2000 14-12-2000 31-08-2004
WO 9013564	A	15-11-1990	AT 102217 T CA 2053921 A1 WO 9013564 A1 DE 69007099 D1 DE 69007099 T2 DK 470980 T3 EP 0470980 A1 ES 2062521 T3 JP 2609764 B2 JP 4502013 T US 5817318 A	15-03-1994 04-11-1990 15-11-1990 07-04-1994 01-06-1994 28-03-1994 19-02-1992 16-12-1994 14-05-1997 09-04-1992 06-10-1998

